Esperion Therapeutics has retained The Chase Group, Inc. to secure an Executive Director, Project Management. This newly created key leadership position will elevate internal collaboration for the organization as it develops and commercializes first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Seasoned executives with CVOT project management leadership are encouraged to contact Bonnie Stofer for confidential consideration at bonnie@chasegroup.com.
Esperion Therapeutics Taps The Chase Group to Fill Newly Created Role
Esperion Therapeutics has retained The Chase Group, Inc. to secure an Executive Director, Project Management. This newly created key leadership position will elevate internal collaboration for the organization as it develops and commercializes first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Seasoned executives with CVOT project management leadership are encouraged to contact Bonnie Stofer for confidential consideration at bonnie@chasegroup.com.- Categories: Life Sciences, Pharmaceutical, Research & Development
The Chase Group Secures Clinical Operations Leadership for Alexza Pharmaceuticals
The Chase Group, committed to executive recruitment in life sciences, is pleased to announce the completion of another search for Alexza Pharmaceuticals, successfully securing Mike…
Arcturus Therapeutics Secures Head of Drug Safety Through Continued Partnership with The Chase Group
The Chase Group’s track record for success continues with another executive placement secured for Arcturus Therapeutics. Entering a new stage in clinical development, Arcturus retained…
Leadership Team Grows at Biologics Consulting Through Partnership with The Chase Group
Biologics Consulting, currently experiencing a season of growth, retained The Chase to build out their leadership team. Tasked with identifying a Regulatory Project Management Lead,…-
The Chase Group Successfully Completes Search for Vice President, Research & Development at Alexza Pharmaceuticals
Alexza Pharmaceuticals stands at the crossroads of innovation and advanced technology with a platform that has the potential to address unmet medical needs in neuroscience…. -
The Chase Group Successfully Places David Geller, MD as Head of Pulmonary & Rare Disease Clinical Development for Arcturus Therapeutics
The Chase Group (TCG) is pleased to announce the successful recruitment of David Geller, MD as the Vice President, Pulmonary and Rare Diseases Clinical Development… 
Drug Safety Leadership Team Grows at Ionis Pharmaceuticals Through Continued Partnership with The Chase Group
Ionis Pharmaceuticals retained The Chase Group to identify and secure the next member of their drug safety leadership team to support a robust and continually…